Epidermal growth factor receptor tyrosine kinase - Globe Thesis

Keyword [Epidermal growth factor receptor tyrosine kinase] Result: 21 - 40 \| Page: 2 of 6
21.	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor As Maintenance Therapy For Advanced Non-Small-Cell Lung Cancer: A Meta-analysis Of Randomized Controlled Trials
22.	Recurrence Patterns In Patients With Advanced Non-small Cell Lung Cancer After Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
23.	RCTs Tyrosine Kinase Inhibitor Medical Treatment Related To The Rash Of Epidermal Growth Factor Receptor
24.	Individualized Therapy Of Advanced Non-small Cell Lung Cancer With Acquired Resistance To Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
25.	Docetaxel Versus EGFR-TKIs As Second-line Treatment Of Patients With Advanced Non-small-cell-lung Cancer
26.	Caveolin-1 Decreases The Sensibility To TKIs In Non-small Cell Lung Cancer Harboring EGFR Mutations
27.	Clinical Observation Of Targeted Drugs As A Therapy On Advanced Non-small Cell Lung Cancer
28.	Erlotinib Enhanced The CIK Cell-mediated Lysis To Lung Adenocarcinoma HCC827 Cells
29.	Efficiency And Safety Of Sequential Treatment Of Icotinib With Chemotherapy In Patients Undergoing Resection Of EGFR Mutation-positive Non-small Cell Lung Cancer
30.	Study On The Structure Activity Relationship Of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
31.	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors In The Treatment Of Central Nerve System Metastases From Non-Small Cell Lung Cancer
32.	The Function Of FBW7 In The Development Of Acquired Resistance To Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors In Non-small Cell Lung Cancer
33.	The Relationship With Different Status Of Epidermal Growth Factor Receptor Gene, Clinicopathological Characteristics,prognosis And Therapeutic Effect Of Patients With Non-small Cell Lung Cancer In Qinghai
34.	The Clinical Observation Of Therapeutic Regimens For Slow Progression Advanced NSCLC After First-line EGFR-TKI Therapy
35.	Study Of The Sensitivity To EGFR-TKI Modulated By P53 On Triple-negative Breast Cancer Cells
36.	The Efficacy Comparison Of Icotinib And Gefitinib In Stage â…£ Lung Adenocarcinoma Patients With EGFR Sensitive Gene Mutation
37.	Clinical Study Of Modified Xiaoji Decoction Combines With Cytokine Induced Killer Cells And Erlotinib In The Treating Of Advanced Non-small Cell Lung Cancer
38.	The Role Of Cancer Stem Cells In EMT-induced Acquired Resistance To EGFR-TKIs In NSCLC Cells
39.	Efficacy Of EGFR-Tyrosine Kinase Inhibitors And Clinical Pathologic Features Analysis Between Exon 19 Deletion And L858R Mutation With Advanced Non-Small Cell Lung Cancer
40.	Hepatocyte Growth Factor Reduces Sensitivity To The Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Gefitinib,in Lung Adenocarcinoma Cells Harboring Wild-TypeEGFR
<<First <Prev Next> Last>> Jump to